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Background: DNA methylation has essential roles in transcriptional regulation, imprinting, X chromosome inactivation
and other cellular processes, and aberrant CpG methylation is directly involved in the pathogenesis of human imprinting
disorders and many cancers. To address the need for a quantitative and highly multiplexed bisulfite sequencing method
with long read lengths for targeted CpG methylation analysis, we developed single-molecule real-time bisulfite
sequencing (SMRT-BS).
Results: Optimized bisulfite conversion and PCR conditions enabled the amplification of DNA fragments up
to ~1.5 kb, and subjecting overlapping 625–1491 bp amplicons to SMRT-BS indicated high reproducibility
across all amplicon lengths (r = 0.972) and low standard deviations (≤0.10) between individual CpG sites sequenced in
triplicate. Higher variability in CpG methylation quantitation was correlated with reduced sequencing depth, particularly
for intermediately methylated regions. SMRT-BS was validated by orthogonal bisulfite-based microarray (r = 0.906; 42
CpG sites) and second generation sequencing (r = 0.933; 174 CpG sites); however, longer SMRT-BS amplicons (>1.0 kb)
had reduced, but very acceptable, correlation with both orthogonal methods (r = 0.836-0.897 and r = 0.892-0.927,
respectively) compared to amplicons less than ~1.0 kb (r = 0.940-0.951 and r = 0.948-0.963, respectively). Multiplexing
utility was assessed by simultaneously subjecting four distinct CpG island amplicons (702–866 bp; 325 CpGs) and 30
hematological malignancy cell lines to SMRT-BS (average depth of 110X), which identified a spectrum of highly
quantitative methylation levels across all interrogated CpG sites and cell lines.
Conclusions: SMRT-BS is a novel, accurate and cost-effective targeted CpG methylation method that is amenable
to a high degree of multiplexing with minimal clonal PCR artifacts. Increased sequencing depth is necessary when
interrogating longer amplicons (>1.0 kb) and the previously reported bisulfite sequencing PCR bias towards
unmethylated DNA should be considered when measuring intermediately methylated regions. Coupled with an
optimized bisulfite PCR protocol, SMRT-BS is capable of interrogating ~1.5 kb amplicons, which theoretically can
cover ~91% of CpG islands in the human genome.
Keywords: DNA methylation, CpG islands, Bisulfite sequencing, Long-read sequencing, Third generation
sequencing, Single-molecule real-time (SMRT) sequencing, Pacific Bioscience* Correspondence: yao.yang@mssm.edu; stuart.scott@mssm.edu
1Department of Genetics and Genomic Sciences, Icahn School of Medicine at
Mount Sinai, New York, NY 10029, USA
Full list of author information is available at the end of the article
© 2015 Yang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Yang et al. BMC Genomics  (2015) 16:350 Page 2 of 10Background
DNA methylation plays an essential role in several crit-
ical cellular processes including gene expression regula-
tion, imprinting and X chromosome inactivation, and
deregulation of the epigenetic machinery has been
directly implicated in both Mendelian disorders and
tumorigenesis [1-4]. In mammals, DNA methylation
predominantly occurs at the 5-position of the cytosine
pyrimidine ring within a CpG dinucleotide. Many tech-
niques to detect CpG methylation have been developed
that can be broadly classified by underlying chemistry,
including bisulfite conversion, methylation sensitive
restriction enzyme analyses, and methylated DNA
immunoprecipitation [5-9]. Each has its own advan-
tages and disadvantages; however, bisulfite conversion
has been the most widely used sample preparation
method for DNA methylation analysis. Common
methylation detection techniques coupled with bisul-
fite conversion include PCR-based assays, microar-
rays, sequencing and other approaches, which differ
in their capacities for single-nucleotide resolution, quanti-
tation, and throughput.
Since the initial 1992 report on CpG methylation de-
tection using bisulfite Sanger sequencing [10], the tech-
nique has been widely used for methylation discovery
and as a diagnostic assay for detecting methylation ab-
normalities at imprinting control regions and the CpG
islands of specific genes [11,12]. Importantly, the on-
going advances in sequencing technology have resulted
in additional platforms available to execute bisulfite
sequencing, including pyrosequencing [13,14] and next-
generation sequencing [15-17]. Although laborious and
low-throughput, bisulfite Sanger sequencing historically
has been one of the most accurate and quantitative tech-
niques to assess CpG methylation. Coupled with PCR
amplicon cloning, bisulfite Sanger sequencing allows for
allele-specific CpG methylation assessment; however,
this is offset by a costly and time-consuming protocol
and an inability to multiplex. Bisulfite pyrosequencing
offers a faster, reproducible and quantitative analysis of
DNA methylation, but is restricted to short read lengths
(~150 bp) with limited capacity for multiplexing [18].
Although a serial pyrosequencing technique using mul-
tiple primers has been developed for extended read
lengths, it is still constrained by short PCR amplicon
lengths [14]. Additionally, it should be noted that all stand-
ard bisulfite conversion-based CpG methylation detection
methods cannot discriminate 5-hydroxymethylcytosine
from 5-methylcytosine. Consequently, oxidative bisulfite
sequencing [19] and microarray [20] methods have
recently been developed to distinguish these related
nucleotides.
In contrast to targeted bisulfite sequencing techniques,
next-generation bisulfite sequencing, including reducedrepresentation bisulfite sequencing (RRBS) [21] and
whole-genome bisulfite sequencing [22], can profile
DNA methylation across an entire genome by quantita-
tively assessing the majority of CpG sites in a single ex-
periment. This unparalleled resolution in methylation
detection is transforming the field of epigenomics; how-
ever, adopting these genome-wide approaches requires
significant bioinformatics expertise and may be prohibi-
tively expensive for certain applications given their low
throughput. An example of multiplexed and targeted bi-
sulfite sequencing using 454 next-generation sequencing
chemistry has been reported; however, the utility of this
highly quantitative method was restricted to read lengths
of only ~130 bp [15].
To address the need for a quantitative and highly
multiplexed targeted bisulfite sequencing method with
long read lengths, we developed a technique that com-
bines bisulfite conversion with third-generation single-
molecule real-time (SMRT) sequencing. Coupled with
an optimized long-range bisulfite amplification protocol
and empowered by the long read lengths of SMRT se-
quencing (up to ~20 kb) [23], multiplexed SMRT bisul-
fite sequencing (SMRT-BS) can accurately measure
CpG methylation across ~1.5 kb regions without the
need for PCR amplicon subcloning. As a cost-effective
alternative to other targeted bisulfite sequencing tech-
niques, SMRT-BS is an efficient and highly quantitative
method for DNA methylation analysis.
Results and discussion
SMRT Bisulfite Sequencing (SMRT-BS) procedure
The SMRT bisulfite sequencing (SMRT-BS) procedure
consists of five steps (Figure 1): (1) bisulfite conversion
of genomic DNA; (2) amplification of bisulfite-treated
DNA using region-specific primers coupled with univer-
sal oligonucleotide tags; (3) re-amplification of amplicon
templates using anti-tag universal primers coupled with
sample-specific multiplexing barcodes; (4) amplicon purifi-
cation, pooling and SMRT sequencing; and (5) CpG
methylation quantitation.
Bisulfite conversion
To maximize the capacity for long-read sequencing,
sample preparation was optimized based on bisulfite
conversion and PCR amplification. Six commercially
available bisulfite conversion kits were tested and the
size distributions of converted DNAs were assessed.
Despite the DNA damage and fragmentation inflicted
by bisulfite conversion [24], five out of the six bisul-
fite conversion kits resulted in DNA fragment distri-
butions with peaks greater than ~2000 bp (Figure 2A),
suggesting that longer amplicons than the typical bi-
sulfite PCR size range (~300-500 bp) [25-27] may be
achievable.
Figure 1 Illustration of the SMRT bisulfite sequencing (SMRT-BS)
procedure. For detailed description of each step see Results
and discussion.
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tial increase in adenine (A) and thymine (T) content and
previous reports have indicated that A/T rich DNA
can be more efficiently amplified by reduced PCR ex-
tension temperatures [28], long-range bisulfite PCR
was evaluated using a gradient of extension tempera-
tures. Treated DNA from each of the bisulfite conver-
sion kits were subjected to PCR with two amplicon
lengths (655 and 1109 bp) and extension temperatures
of 65°C, 68°C, and 72°C (Figure 2B). These data indi-
cated that two bisulfite conversion kits (Epigentek
Methylamp and Qiagen EpiTect) and a PCR extension
temperature of 65°C resulted in the most consistent
amplification of the longer 1109 bp product using the
reported conditions.
Long-range amplification and SMRT-BS quality filtering
To determine the maximum PCR amplicon size achiev-
able with bisulfite converted DNA from the Qiagen and
Epigentek kits, eight primer sets were tested that ranged
in amplicon length from 655–4027 bp (Figure 2C,
Additional file 1: Table S1). All primers were previously
validated by short-length PCR to ensure their capacity
for amplification. These results indicated that bisulfitePCR with DNA converted by the Epigentek Methylamp
kit using the reported conditions could amplify products
up to ~2.0 kb (Figure 2D), although amplification of the
2.0 kb product was not generally consistent. The ~1.5 kb
product was consistently amplified and was determined
to be the approximated upper limit of stable bisulfite
PCR using these conditions.
Notably, the ability to amplify longer amplicons follow-
ing bisulfite conversion with the Epigentek Methylamp
kit was not reflective of poor bisulfite conversion effi-
ciency as the cytosine conversion rate of amplicons sub-
jected to SMRT-BS (detailed below) had an average
conversion rate of 97.0%. All amplicons with conversion
rates less than 95% (6.8% of all reads) were filtered prior
to CpG methylation quantitation, which increased the
average conversion rate to 97.3%. In addition, potential
clonal PCR artifacts, as defined by identical patterns of
both CpG and non-CpG cytosines throughout the ampli-
cons (0.3% of all reads) [29], were filtered prior to CpG
methylation quantitation.
Long-read SMRT-BS and reproducibility
To assess if long-range PCR amplification introduces
any bias based on methylation level, CpG islands
with low (TUBGCP3), intermediate (MEST), and high
(EHPA8) methylation levels (previously determined by
Illumina HumanMethylation450 BeadChip analysis)
were subjected to SMRT-BS with four overlapping
amplicons ranging from 625–1491 bp (Figure 3A;
Additional file 1: Table S2). In addition, reproducibility
was measured by simultaneously sequencing each of
these four amplicons in triplicate using independent
PCR reactions and unique barcodes. The methylation
levels of all CpG sites interrogated were quantitated and
are illustrated as a heat map in Figure 3B. The reprodu-
cibility of SMRT-BS was very high for all methylation
levels and amplicon sizes, with an average overall correl-
ation of r = 0.972 ± 0.024 between independent triplicate
amplicons (Figure 3C). However, despite the overall high
reproducibility, correlation with the longer amplicons
was reduced compared to the correlation observed be-
tween shorter amplicons (Figure 3C).
In addition to assessing the correlation between overall
amplicon methylation, individual CpG site methylation
levels were compared and the average standard devia-
tions (SDs) between triplicates in each tested amplicon
are illustrated in Figure 3D. Of note, the median SDs
for all CpG sites across all triplicate amplicons was
less than ~0.10. The unmethylated and highly meth-
ylated CpG islands were very consistent at all ampli-
con lengths and replicates (median SD = 0.009, 0.009,
0.023 and 0.016 for the unmethylated amplicons, and
SD = 0.010, 0.012, 0.032 and 0.024 for the highly methyl-
ated amplicons) (Figure 3D). However, analysis of the
Figure 2 Bisulfite conversion and long-range amplification. (A) Six commercially available bisulfite conversion kits were tested and treated DNAs
were examined using an Agilent 2100 Bioanalyzer to assess size distributions. (B) Two bisulfite-converted DNAs from each of the six kits were
subjected to PCR with two amplicons (655 and 1109 bp) and three different extension temperatures (65°C, 68°C and 72°C) to assess capacity for
long amplicon amplification. Bisulfite-converted DNA from two kits (Epigentek Methylamp and Qiagen EpiTect) with a PCR extension temperature
of 65°C had the most robust amplification of the longer 1109 bp amplicon. (C) Eight amplicons ranging in size from 655–4027 bp (overlapping
the MEST CpG island) were designed to determine the upper amplicon size limit of bisulfite PCR. (D) Agarose gel image of bisulfite PCR with
the eight primer sets using DNA converted by the Epigentek Methylamp and Qiagen EpiTect kits revealing stable amplification of the 1631 bp
amplicon with the Epigentek Methylamp converted DNA and the reported PCR conditions.
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the four different sized amplicons identified CpG site
methylation median SDs of 0.044, 0.040, 0.097 and 0.111,
respectively.
As also illustrated in Figure 3d, the amplicons that
were greater than ~1 kb had lower SMRT-BS sequencing
depth than the shorter amplicons despite being pooled
with equal numbers of molecules. This resulted in
methylation reproducibility being positively correlated
with sequencing depth and negatively correlated with
amplicon length. Consequently, these data underscore
the need for increased sequencing depth for regions with
intermediate methylation levels compared to those with
low or high methylation levels to achieve similar confi-
dence intervals and margins of error. Shorter amplicons
may get preferentially sequenced when pooled with lon-
ger amplicons, which could be counterbalanced by
increasing the molecule quantity of longer amplicons in
the SMRT sequencing reaction when multiplexed with
shorter amplicons. In addition, the increased variability
observed in the intermediate methylation amplicons also
suggests that PCR bias towards unmethylated DNA may
occur, as has previously been reported with traditional
bisulfite sequencing [30].Validation of SMRT-BS methylation quantitation
Validation of SMRT-BS was accomplished by comparing
identified TUBGCP3, MEST, and EHPA8 CpG methyla-
tion levels from peripheral blood DNA samples with
methylation data on the same samples from two
independent technologies, the HumanMethylation450
BeadChip (42 CpG sites) and the SureSelect™ Human
Methyl-Seq target enrichment next-generation sequen-
cing platform (174 CpG sites). The SMRT-BS methyla-
tion levels of these CpG sites ranged from 0 to 1.0 and
had an average sequencing depth of 106X. Correlation
analyses indicated that the identified SMRT-BS
methylation levels were consistent with the two or-
thogonal technologies with an overall r = 0.906 ± 0.052
and r = 0.933 ± 0.031, respectively. The lower correlation
observed with the HumanMethylation450 BeadChip data
was likely due to fewer CpG sites included in the analysis.
Stratifying the correlation analyses by amplicon length
indicated that although the overall correlations were very
good for all lengths, reduced correlation was observed
with the amplicons greater than 1.0 kb than those less
than 1.0 kb (Figure 4). These results are consistent with
the increased SD observed between replicates of the lon-
ger amplicons (Figure 3D) and are likely influenced, in
Figure 3 Long-read SMRT-BS and reproducibility. (A) To assess if amplicon length influenced methylation quantitation, CpG islands with
previously determined low (TUBGCP3), intermediate (MEST), and high (EHPA8) methylation levels were subjected to SMRT-BS with four
overlapping amplicons ranging from 625–1491 bp. Each amplicon was designed to completely or partially cover the CpG island (highlighted
by green bars) and each was independently amplified in triplicate to determine reproducibility. (B) A heat map of CpG methylation identified
by SMRT-BS for amplicons illustrated in (A), demonstrating strong consistency with methylation quantitation between triplicate amplicons
and between amplicon lengths. (C) A heat map of correlation between triplicate amplicons and across the different sized amplicons identifying
strong overall correlation (0.972 ± 0.024), but reduced correlation with the longer amplicons. (D) Box plots of the standard deviation of CpG site
methylation levels between triplicate amplicons for all tested regions (low methylation: blue; intermediate methylation: grey; high methylation: red).
Of note, moderately increased variability in CpG site methylation levels was observed with the intermediately methylated CpG island (MEST) and
with amplicons greater than ~1 kb (see Results and discussion). Overlaid is a green line graph of sequencing depth for each amplicon, suggesting
preferential sequencing of the shorter amplicons compared to the longer amplicons and the influence of reduced sequencing depth on CpG site
methylation level reproducibility.
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amplicons (as noted above). However, the pattern of shifted
intermediate methylation levels observed in the validation
analyses also support the aforementioned possibility of PCR
bias towards unmethylated DNA that has been previously
reported with amplicon bisulfite sequencing [30].SMRT-BS multiplexing and utility
To evaluate the utility of SMRT-BS with multiplexed
amplicons and specimens, four distinct CpG island
amplicons [AFAP1 (798 bp), CEBPA (702 bp and
866 bp), CDKN2A (770 bp)] and 30 hematological ma-
lignancy cell lines were simultaneously subjected to
SMRT-BS (Additional file 1: Table S3). The average se-
quencing depth was 110X for each of the 120 ampli-
cons, which identified a spectrum of highly quantitativemethylation levels across all cell lines and interro-
gated CpG sites (Figure 5A). The CDKN2A tumor
suppressor gene is commonly deleted in hematological
cancers and those cell lines with CDKN2A deletions
could not amplify products. Of note, one of the cell
lines included in the SMRT-BS multiplexing analysis
(K562) was previously subjected to RRBS methylation
analysis through the publically available ENCODE
project [31]. There were 129 CpG sites covered in
this cell line by both data sets, with average SMRT-
BS and RRBS sequencing depths of 101X and 31X,
respectively. Among these CpG sites, 78 had >20X
coverage by RRBS, and the Pearson correlation be-
tween SMRT-BS and RRBS methylation levels among
these 78 CpG sites was 0.900 (Figure 5B), further
supporting the overall accuracy of SMRT-BS methy
lation quantitation.
Figure 4 SMRT-BS validation. (A) Methylation quantitation by SMRT-BS
of 42 CpG sites was compared to available data on the same sample
using the HumanMethylation450 BeadChip (450K Array), resulting in an
overall correlation of 0.906 ± 0.052. Correlation analyses were
stratified by amplicon lengths, indicating a reduction in correlation
with longer amplicons and possible PCR bias towards unmethylated
DNA for the intermediate methylation region (see Results and
discussion). (B) Methylation quantitation by SMRT-BS of 174
CpG sites was compared to available data on the same sample
using the SureSelect™ Human Methyl-Seq target enrichment next
generation sequencing platform (MethylSeq), resulting in an overall
correlation of 0.933 ± 0.031. Correlation analyses were stratified by
amplicon lengths, indicating a reduction in correlation with longer
amplicons and possible PCR bias towards unmethylated DNA for the
intermediate methylation region (see Results and discussion).
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Many techniques have been developed to measure CpG
methylation, which differ widely in their chemistry, sam-
ple requirement, resolution, capacity for quantitation,throughput, accessibility and cost (for recent review, see
[8]). Although genome-wide sequencing approaches are
often desirable, the immediate benefits in CpG coverage
can be offset by high per sample costs, a low throughput,
and the need for computational expertise. Consequently,
targeted approaches to detect CpG methylation are still
widely used and continually developed, now often coup-
ling bisulfite conversion with next-generation sequen-
cing [15-17]. However, the paucity of targeted bisulfite
sequencing techniques capable of examining amplicons
longer than the typical bisulfite PCR size range (~300-
500 bp) [15-17,25-27] prompted our development of
SMRT-BS.
Although SMRT sequencing is capable of directly de-
tecting modified nucleotides by their unique polymerase
kinetics without bisulfite conversion [32], the introduc-
tion of an amplification step abolishes its ability to de-
tect any epigenetic modifications of template DNA. A
key component to the development of SMRT-BS was
the optimization of bisulfite conversion and PCR, which
resulted in amplicons up to ~1.5-2.0 kb from bisulfite-
converted DNA. Subjecting these amplicons to multi-
plexed SMRT-BS indicated that the technique was
reproducible and highly concordant with other lower
throughput quantitative CpG methylation methods.
However, the increased variability observed with SMRT-BS
of intermediately methylated regions must be acknowl-
edged as a potential limitation that may be mitigated
by increased sequencing depth. Similarly, as has pre-
viously been reported for amplicon bisulfite sequen-
cing [30], it should be noted that SMRT-BS of
intermediately methylated regions may also be influ-
enced by PCR bias towards unmethylated DNA. To
account for this known problem inherent to ampli-
con bisulfite sequencing, calibration strategies using
standard curves of methylation controls have been
reported if needed [30,33].
As a targeted amplicon sequencing method and an ex-
tension of previous bisulfite sequencing techniques,
SMRT-BS is capable of a high degree of multiplexing
and sequencing depth for accurate methylation quantita-
tion with negligable clonal PCR artifacts. Importantly,
this technique also takes advantage of the long read
lengths achievable with SMRT sequencing, which allows
for more thorough regional CpG methylation assessment
and increases the capacity for studying the relationship
between phased single nucleotide variants and allele-
specific CpG methylation. Additional potential applica-
tions of SMRT-BS include targeted panels for diagnostic
CpG methylation detection, and multiplexed interrogation
of candidate CpG methylation sites for epigenome-
wide association study (EWAS) [34,35] replication
analyses. Notably, the size distribution of all CpG
islands in the hg19 human genome reference sequence
Figure 5 SMRT-BS utility and multiplexing. (A) Heat map of SMRT-BS methylation quantitation results for four CpG island amplicons [AFAP1
(798 bp), CEBPA (702 bp and 866 bp), CDKN2A (770 bp)] and 30 hematological malignancy cell lines. CDKN2A deletion is illustrated by grey bars.
(B) SMRT-BS methylation results of 79 CpG sites for the K562 cell line were compared to available RRBS data from the ENCODE project [31],
revealing a correlation of 0.900.
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[36]) suggests that the ability of SMRT-BS to measure
DNA methylation across ~1.5 kb amplicons could theor-
etically interrogate ~91% of all the CpG islands in the hu-
man genome.
Methods
Specimens and cell lines
Peripheral blood samples from healthy donors who self-
reported their racial background and gave informed con-
sent for the use of their DNA for research were obtained
from the New York Blood Center with IRB approval as
previously defined [37]. All personal identifiers were re-
moved, and isolated DNA samples were tested anonym-
ously. Genomic DNA was isolated using the Puregene®
DNA Purification kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions.
The human acute myeloid leukemia (AML193, THP-1,
KG1A, MV4-11, KCL-22, OCI-M1), chronic myeloid
leukemia (LAMA-84, JURL-MK1, K562, KU-812),
anaplastic large cell lymphoma (SU-DHL-1, SUP-M2,
SR786, DEL), plasma cell leukemia (SK-MM-2, L-363,
AMO-1, JJN), Burkitts lymphoma (BL-41, BL-70, CA-46,
RAJI), B–cell lymphoma (DOHH, OCI-LY-2, OCI-LY-3,
OCI-LY-7, OCI-LY-8, OCI-LY-10, OCI-LY-19) and
multiple myeloma (KMS-12-BM) cell lines were ob-
tained from either the Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany) or the American Type Culture
Collection (ATCC; Manassas, VA, USA). All cell lines were
cultured as per recommended conditions. Genomic DNAs
were isolated using the DNeasy Blood and Tissue Kit
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions.Bisulfite treatment
All bisulfite treatments of genomic DNAs (1 μg) were
performed according to the manufacturer’s instructions.
Six commercial kits were evaluated: (1) Diagenode
Premium Bisulfite Kit, (2) Epigentek Methylamp DNA
Modification Kit, (3) NEB EpiMark Bisulfite Conversion
Kit, (4) Promega MethylEdge Bisulfite Conversion
System, (5) Qiagen EpiTect Bisulfite Kit, and (6) Zymo
EZ-DNA Methylation-Gold Kit. Bisulfite-treated DNAs
were quantified using the NanoDrop 1000 and sized
with a 2100 Bioanalyzer using the RNA6000 Pico kit
(Agilent Technologies).
Bisulfite PCR
First-step PCR reactions were performed in 20 μl
containing ~50-100 ng of bisulfite-treated DNA, 1X
PCR Buffer, 0.2 mM of each dNTP, 0.2 μM forward
and reverse region-specific primers (Additional file 1:
Tables S1-S3), and 1.0 unit of TaKaRa Taq HS (Clontech
Laboratories, Inc., Mountain View, CA, USA). Amplifica-
tion consisted of an initial denaturation step at 94°C for
2 min followed by 35 amplification cycles (94°C for 20 sec,
55°C for 45 sec, and 65°C for 1 min/kb + 30 seconds) and
a final incubation at 65°C for 5 min (unless otherwise
noted). Second-step PCR reactions were carried out using
1 μl of a 1:50 dilution of first-step PCR product in a total
volume of 25 μl with the same conditions as first-step
PCR, but using barcoded universal primers and an anneal-
ing temperature of 60°C.
Single-Molecule Real-Time (SMRT) sequencing
All PCR amplicons were purified using the QiaQuick
PCR Purification Kit (Qiagen) and quantified by Nanodrop
1000. After purification, PCR amplicons were pooled with
Figure 6 Illustration of the SMRT-BS analysis pipeline. For detailed
description of each step see Methods.
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of each amplicon was calculated by the following formula:




Where Vi is the volume of each PCR amplicon, M is
the total mass of pooled PCR amplicons, Li is the length
of each amplicon, n is the total number of samples, Ci is
the concentration of each amplicon and m is the total
number of amplicons. A total of 500 ng of pooled PCR
amplicons were submitted for SMRT sequencing.
Single-molecule real-time (SMRT) sequencing was
performed according to the P5-C3 Pacific Biosciences
protocol with a movie collection time of 180 minutes. In
brief, pooled PCR amplicons were quantified using
Qubit fluorometric analysis (Life Technologies) and a
Bioanalysis 12000 chip (Agilent Technologies) to assess
PCR amplicon quality, size, and quantity. Additionally,
barcoded and pooled amplicons were purified using
Ampure XP Solid Phase Reversible Immobilization
(Beckman Coulter) at 0.8-fold volume. SMRTbell librar-
ies were constructed using end-repair, ligation, and exo-
nuclease purification strategies detailed in the Pacific
Biosciences P5-C3 Template Preparation Kit protocols.
SMRTbell templates were then bound to polymerase
molecules for 4 hours at 25°C using 3 nM of the ampli-
con SMRTbell library and excess P5 DNA polymerase at
a concentration of 9 nM as previously described [38].
The polymerase-template complexes were immobilized
at 250 pM for 30 min on nanofabricated SMRTcells con-
taining an array of zero-mode waveguides (ZMWs), and
ZMWs were analyzed for sequencing to generate reads
using a 1x180-minute collection protocol. Circular con-
sensus sequencing (CCS) was employed using multiple
passes on each SMRTbell to generate CCS reads with
higher accuracy for data analysis. The ‘Reads of Insert’
pipeline was utilized with a filter of 85% accuracy
and 1-pass prior to downstream analyses.
SMRT-BS data analysis
The SMRT-BS data analysis workflow is illustrated in
Figure 6. Briefly, sequencing reads in FASTQ format
were demultiplexed and trimmed using NGSutils [39].
Two mismatches (including insertions/deletions) were
allowed in each 18 bp barcode, and both universal
primers and barcodes were trimmed prior to down-
stream analyses. Only reads longer than 50 bp were used
for subsequent methylation extraction. Bismark [40]
(with bowtie 2 [41]) was used for alignment, and the
generated SAM files were subjected to read filtering (see
Results and discussion) and CpG methylation quantita-
tion using an in-house developed Python script. Any CpG
sites with sequencing depth lower than 10X were excludedfrom further analyses. Please note that a freely available
program to analyze SMRT-BS and other high-throughput
bisulfite sequencing data (HiTMAP: High Throughput
Methylation Analysis Program) is in development and a
manuscript detailing its functionality and accessibility is in
preparation.
Infinium HumanMethylation450 BeadChip (450K-array)
Methylation data from SMRT-BS was validated against
overlapping CpG site methylation data derived from the
Infinium HumanMethylation450 BeadChip (450K-array;
Illumina, Inc., San Diego, CA, USA). The samples were
processed according to the manufacturer’s instructions
by the Genomics Core Laboratory at the Icahn School of
Medicine at Mount Sinai without any modification to
the manufacturer’s protocol. 450K-array data were ob-
tained and normalized using GenomeStudio® software
(Illumina) according to the manufacturer’s instructions
and the Illumina Methylation Analyzer (IMA) R package
[42]. 450K-array probes with detection p-values greater
than 0.01 or with missing values were removed prior to
further analyses. Multiple-mapped probes with less than
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aligner and removed to avoid potential errors of unspe-
cific binding. In addition, probes that included known
single-nucleotide polymorphisms according to 450K-array
annotation were removed and peak-based normalization
was performed using IMA.
SureSelect™ human Methyl-Seq
Methylation data from SMRT-BS was also validated
against overlapping CpG site methylation data derived
from the SureSelect™ Human Methyl-Seq (Agilent
Technologies, Santa Clara, CA, USA) target enrichment
system. Libraries were prepared according to the manu-
facturer’s instructions without any modification to
the manufacturer’s protocol. In brief, 2 μg of genomic
DNAs were sheared by a Covaris E210 to fragments
of ~150 bp, end-repaired, 3’ end-adenylated and ligated
with methylated adaptors. Pre-prepared DNA fragments
were hybridized to SureSelect™ Human Methyl-Seq cap-
ture libraries, and target captured DNAs were treated
with bisulfite, subjected to eight PCR cycles to enrich
adaptor added fragments and six PCR cycles to add mul-
tiplexing barcodes. Sequencing was accomplished using
a HiSeq 2000 (Illumina) and 100 bp single-read sequen-
cing with one lane per two samples. Raw sequencing
data was analyzed with Bismark [40] to extract DNA
methylation information.
Availability of supporting data
Data sets supporting the results of this study were
uploaded to public data repositories for open access.
The SMRT-BS sequencing FASTQ data are available
from the NCBI Sequence Read Archive (SRA) using
the SRX977650 and SRX977540 experiment identi-
fiers: http://www.ncbi.nlm.nih.gov/sra/SRX977650[accn]
and http://www.ncbi.nlm.nih.gov/sra/SRX977540[accn].
The 450K-array and Methyl-Seq validation data are avail-
able from the LabArchives Electronic Laboratory Note-
book (DOI: 10.6070/H45H7D8C).
Additional file
Additional file 1: Includes three Supplemental Tables listing the
oligonucleotide primers used for bisulfite PCR.
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